流感疫苗市场机会、成长要素、产业趋势分析及2026-2035年预测。

预计到 2025 年，全球流感疫苗市场价值将达到 90 亿美元，并有望以 7% 的复合年增长率成长，到 2035 年达到 174 亿美元。

流感疫苗市场是指致力于研发、生产和分发疫苗以保护人们免受流行流感病毒侵害的全球生态系统。这些疫苗旨在降低感染率、减轻疾病严重程度并增强群体免疫力，尤其是在併发症高风险族群中。整个产业采用多种疫苗技术，包括为增强免疫保护和应对病毒变异株而开发的多种免疫平台。一个显着的行业趋势是转向先进的疫苗研发技术，旨在提高生产效率和免疫免疫抗原性。传统生产方法越来越多地得到现代製造平台的支持，这些平台能够提高抗原相容性、增加产量并提高生产计划的灵活性。政府主导的免疫接种倡议和机构采购计划也支持长期需求成长。促进年度免疫接种的公共卫生政策，加上国家储备计划和扩大医疗保险覆盖范围，正在推动疫苗接种的持续进行。这些政策框架持续刺激对研发和生产能力的投资，同时应对与疫苗效力和生产计画相关的长期挑战。

预计到2025年，灭活疫苗市场份额将达到85.7%，并在2026年至2035年间以6.9%的复合年增长率增长。该细分市场凭藉其良好的安全性记录和对不同人群的广泛适用性，保持着主导地位。灭活流感疫苗在免疫规划中持续广泛应用，因为它们能够在不引入可复製病毒颗粒的情况下诱发保护性免疫反应。其安全性使其适用于包括不同健康状况人群在内的各类人群，这也推动了其在国家免疫战略中的广泛应用。

预计2025年，四价流感疫苗市场规模将达到79亿美元。这类疫苗之所以在该市场占据主导地位，是因为它们能够在单一配方中提供多种流行流感病毒株的广泛保护。更广泛的病毒株覆盖范围降低了疫苗成分与季节性病毒模式不匹配的风险，从而提高了免疫宣传活动的整体有效性。这种更全面的保护能力使四价疫苗成为大规模免疫接种倡议的首选。此外，这些疫苗能够适应季节性变化，有助于改善临床疗效，降低住院率，并在流感流行季节更好地保护公众健康。

预计到2025年，北美流感疫苗市占率将达到44.9%。该地区凭藉其先进的医疗基础设施、完善的法规结构以及公众对预防医学的高度重视，保持着强劲的市场地位。美国完善的疾病监测系统和鼓励常规疫苗接种的医疗政策进一步巩固了其在区域市场的主导地位。针对广大民众推广年度流感疫苗接种的公共卫生计画持续支撑着强劲的需求，并推动了儿童、成人和高风险族群疫苗市场的持续成长。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 流感疫情蔓延
    • 政府扩大卫生倡议和免疫接种计划
    • 疫苗技术的进步
  • 产业潜在风险与挑战
    • 疫苗研发高成本
    • 疫苗生产週期延长
  • 市场机会
    • 扩大通用型和频谱流感疫苗的接种范围
    • 扩大儿童和孕妇免疫接种计划。
• 成长潜力分析
• 监理情势（基于初步调查）
• 管道分析
• 专利分析
• 技术与创新趋势（基于初步调查）
  • 目前技术
  • 新兴技术
• 未来市场趋势（基于初步研究）
• 人工智慧和生成式人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估计与预测：疫苗类型，2022-2035年

• 失活
• 减毒活病毒疫苗
• 重组

第六章 市场估计与预测：依适应症划分，2022-2035年

• 四价
• 三价

第七章 市场估计与预测：依技术划分，2022-2035年

• 蛋製品
• 基于细胞
• 重组技术

第八章 市场估计与预测：依流感类型划分，2022-2035年

• 季节性
• 大流行

第九章 市场估计与预测：依年龄组别划分，2022-2035年

• 儿童
• 成人

第十章 市场估计与预测：依给药途径划分，2022-2035年

• 注射
• 鼻喷雾

第十一章 市场估计与预测：依最终用途划分，2022-2035年

• 医院
  • 民众
  • 私人的
• 诊所
• 其他最终用户

第十二章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十三章：公司简介

• AstraZeneca
• Bharat Biotech
• Cadila Healthcare（Zydus Lifesciences）
• CSL Seqirus
• Denka Seiken
• GlaxoSmithKline
• Sanofi
• Serum Institute of India
• Sinovac Biotech
• SK bioscience
• Viatris
• GC Biopharma
• Bio Farma

The Global Influenza Vaccines Market was valued at USD 9 billion in 2025 and is estimated to grow at a CAGR of 7% to reach USD 17.4 billion by 2035.

The influenza vaccines market represents the global ecosystem dedicated to the development, production, and distribution of vaccines that help protect populations from circulating influenza viruses. These vaccines are designed to lower infection rates, minimize the severity of illness, and strengthen community-level immunity, particularly among individuals who are more vulnerable to complications. Various vaccine technologies are utilized across the industry, including multiple immunization platforms developed to improve immune protection and respond to evolving viral strains. A notable industry trend involves the transition toward advanced vaccine development technologies aimed at improving production efficiency and immunogenic performance. Traditional production methods are increasingly supported by modern manufacturing platforms that enable improved antigen matching, higher output levels, and more flexible production timelines. Government-backed immunization initiatives and institutional procurement programs are also supporting long-term demand growth. Public health policies that promote annual vaccination, combined with national stockpiling programs and broader healthcare coverage, are encouraging consistent vaccine uptake. These policy frameworks continue to stimulate investment in research, development, and manufacturing capacity while addressing longstanding challenges related to vaccine effectiveness and production timelines.

The inactivated segment held 85.7% share in 2025 and is projected to grow at a CAGR of 6.9% throughout 2026-2035. This segment maintains a leading position due to its well-established safety record and broad applicability across diverse population groups. Inactivated influenza vaccines remain widely utilized in immunization programs because they generate protective immune responses without introducing replicating viral particles. Their safety profile makes them suitable for use across a wide demographic range, including individuals with varying health conditions, which reinforces their widespread adoption within national vaccination strategies.

The quadrivalent vaccine segment generated USD 7.9 billion in 2025. These vaccines dominate the segment because they provide expanded protection against multiple circulating influenza virus strains within a single formulation. Broader strain coverage helps reduce the risk of mismatch between vaccine composition and seasonal viral patterns, which improves the overall effectiveness of vaccination campaigns. This expanded protective capability has made quadrivalent vaccines a preferred choice for large-scale immunization initiatives. In addition, the ability of these vaccines to address seasonal variability contributes to improved clinical outcomes, lower hospitalization rates, and stronger public health protection during influenza seasons.

North America Influenza Vaccines Market accounted for 44.9% share in 2025. The region maintains its strong position due to its advanced healthcare infrastructure, supportive regulatory frameworks, and high public awareness regarding preventive healthcare practices. The leadership of United States within the regional market is reinforced by well-established disease surveillance systems and healthcare policies that encourage routine vaccination. Public health programs that promote annual influenza vaccination across broad population groups continue to support strong demand, contributing to consistent market expansion across pediatric, adult, and high-risk populations.

Key participants operating in the Global Influenza Vaccines Market include Sanofi, GlaxoSmithKline, AstraZeneca, CSL Seqirus, Serum Institute of India, Sinovac Biotech, SK Bioscience, Viatris, GC Biopharma, Bharat Biotech, Cadila Healthcare (Zydus Lifesciences), Denka Seiken, and Bio Farma. Companies operating in the Global Influenza Vaccines Market are implementing several strategies to strengthen their competitive presence and expand market share. Leading vaccine manufacturers are investing heavily in research and development to advance next-generation vaccine platforms that offer improved immune responses and faster production capabilities. Strategic partnerships with government health agencies and international health organizations are helping companies secure large procurement contracts and strengthen supply networks. Firms are also expanding manufacturing capacity and adopting advanced production technologies to support large-scale vaccination programs. In addition, companies are increasing their focus on global distribution infrastructure and regional market expansion to improve vaccine accessibility.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Vaccine type trends
  • 2.2.3 Indication trends
  • 2.2.4 Flu type trends
  • 2.2.5 Age group trends
  • 2.2.6 Route of administration trends
  • 2.2.7 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of influenza
    • 3.2.1.2 Rising government health initiatives and immunization programs
    • 3.2.1.3 Advancements in vaccine technologies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with vaccine development
    • 3.2.2.2 Longer vaccine production timelines
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of universal and broader-spectrum influenza vaccines
    • 3.2.3.2 Growth in pediatric and maternal immunization programs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis
• 3.6 Patent analysis
• 3.7 Technology and innovation landscape (Driven by Primary Research)
  • 3.7.1 Current technologies
  • 3.7.2 Emerging technologies
• 3.8 Future market trends (Driven by Primary Research)
• 3.9 Impact of AI and generative AI on the market
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Inactivated
• 5.3 Live attenuated
• 5.4 Recombinant

Chapter 6 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Quadrivalent
• 6.3 Trivalent

Chapter 7 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Egg-based
• 7.3 Cell-based
• 7.4 Recombinant technology

Chapter 8 Market Estimates and Forecast, By Flu Type, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Seasonal
• 8.3 Pandemic

Chapter 9 Market Estimates and Forecast, By Age Group, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pediatric
• 9.3 Adults

Chapter 10 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 Injection
• 10.3 Nasal spray

Chapter 11 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 11.1 Key trends
• 11.2 Hospitals
  • 11.2.1 Public
  • 11.2.2 Private
• 11.3 Clinics
• 11.4 Other end users

Chapter 12 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Netherlands
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 India
  • 12.4.3 Japan
  • 12.4.4 Australia
  • 12.4.5 South Korea
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Argentina
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 UAE

Chapter 13 Company Profiles

• 13.1 AstraZeneca
• 13.2 Bharat Biotech
• 13.3 Cadila Healthcare (Zydus Lifesciences)
• 13.4 CSL Seqirus
• 13.5 Denka Seiken
• 13.6 GlaxoSmithKline
• 13.7 Sanofi
• 13.8 Serum Institute of India
• 13.9 Sinovac Biotech
• 13.10 SK bioscience
• 13.11 Viatris
• 13.12 GC Biopharma
• 13.13 Bio Farma